Literature DB >> 25635267

The viral transcription group determines the HLA class I cellular immune response against human respiratory syncytial virus.

Carolina Johnstone1, Elena Lorente1, Alejandro Barriga1, Eilon Barnea2, Susana Infantes1, François A Lemonnier3, Chella S David4, Arie Admon2, Daniel López5.   

Abstract

The cytotoxic T-lymphocyte-mediated killing of virus-infected cells requires previous recognition of short viral antigenic peptides bound to human leukocyte antigen class I molecules that are exposed on the surface of infected cells. The cytotoxic T-lymphocyte response is critical for the clearance of human respiratory syncytial virus infection. In this study, naturally processed viral human leukocyte antigen class I ligands were identified with mass spectrometry analysis of complex human leukocyte antigen-bound peptide pools isolated from large amounts of human respiratory syncytial virus-infected cells. Acute antiviral T-cell response characterization showed that viral transcription determines both the immunoprevalence and immunodominance of the human leukocyte antigen class I response to human respiratory syncytial virus. These findings have clear implications for antiviral vaccine design.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25635267      PMCID: PMC4390268          DOI: 10.1074/mcp.M114.045401

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  52 in total

1.  HIV envelope protein inhibits MHC class I presentation of a cytomegalovirus protective epitope.

Authors:  D López; Y Samino; U H Koszinowski; M Del Val
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

Review 2.  Immunodominance: a pivotal principle in host response to viral infections.

Authors:  Ali Akram; Robert D Inman
Journal:  Clin Immunol       Date:  2012-02-10       Impact factor: 3.969

3.  Unusual viral ligand with alternative interactions is presented by HLA-Cw4 in human respiratory syncytial virus-infected cells.

Authors:  Susana Infantes; Elena Lorente; Juan José Cragnolini; Manuel Ramos; Ruth García; Mercedes Jiménez; Salvador Iborra; Margarita Del Val; Daniel López
Journal:  Immunol Cell Biol       Date:  2010-10-26       Impact factor: 5.126

4.  H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.

Authors:  H Firat; F Garcia-Pons; S Tourdot; S Pascolo; A Scardino; Z Garcia; M L Michel; R W Jack; G Jung; K Kosmatopoulos; L Mateo; A Suhrbier; F A Lemonnier; P Langlade-Demoyen
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

5.  Role of metalloproteases in vaccinia virus epitope processing for transporter associated with antigen processing (TAP)-independent human leukocyte antigen (HLA)-B7 class I antigen presentation.

Authors:  Elena Lorente; Ruth García; Carmen Mir; Alejandro Barriga; François A Lemonnier; Manuel Ramos; Daniel López
Journal:  J Biol Chem       Date:  2012-02-01       Impact factor: 5.157

6.  Sendai virus gene expression in lytically and persistently infected cells.

Authors:  H E Homann; P H Hofschneider; W J Neubert
Journal:  Virology       Date:  1990-07       Impact factor: 3.616

7.  Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

Authors:  A H Cherrie; K Anderson; G W Wertz; P J Openshaw
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.

Authors:  Esther Tapia; Eva Pérez-Jiménez; Laura López-Fuertes; Rosa Gonzalo; M Magdalena Gherardi; Mariano Esteban
Journal:  Microbes Infect       Date:  2003-02       Impact factor: 2.700

9.  Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination.

Authors:  Wolfgang Kastenmuller; Georg Gasteiger; Julian H Gronau; Robert Baier; Ronny Ljapoci; Dirk H Busch; Ingo Drexler
Journal:  J Exp Med       Date:  2007-08-20       Impact factor: 14.307

10.  Concerted in vitro trimming of viral HLA-B27-restricted ligands by human ERAP1 and ERAP2 aminopeptidases.

Authors:  Elena Lorente; Alejandro Barriga; Carolina Johnstone; Carmen Mir; Mercedes Jiménez; Daniel López
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more
  5 in total

Review 1.  Proteomic contributions to our understanding of vaccine and immune responses.

Authors:  Allison C Galassie; Andrew J Link
Journal:  Proteomics Clin Appl       Date:  2015-09-10       Impact factor: 3.494

2.  Structural and Nonstructural Viral Proteins Are Targets of T-Helper Immune Response against Human Respiratory Syncytial Virus.

Authors:  Elena Lorente; Alejandro Barriga; Eilon Barnea; Carmen Mir; John A Gebe; Arie Admon; Daniel López
Journal:  Mol Cell Proteomics       Date:  2016-04-18       Impact factor: 5.911

3.  Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2).

Authors:  Elena Lorente; Miguel G Fontela; Eilon Barnea; Antonio J Martín-Galiano; Carmen Mir; Begoña Galocha; Arie Admon; Pilar Lauzurica; Daniel López
Journal:  Mol Cell Proteomics       Date:  2020-04-07       Impact factor: 5.911

4.  Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence.

Authors:  Elena Lorente; Alejandro Barriga; Eilon Barnea; Concepción Palomo; Juan García-Arriaza; Carmen Mir; Mariano Esteban; Arie Admon; Daniel López
Journal:  PLoS Negl Trop Dis       Date:  2019-07-05

Review 5.  Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.

Authors:  Etienne Caron; Daniel J Kowalewski; Ching Chiek Koh; Theo Sturm; Heiko Schuster; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2015-12       Impact factor: 5.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.